drugset
drugset / Trial / NCT04812925

A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

NCT04812925 ↗

Phase 3 Active not recruiting 173 enrolled argenx
NaSingle-groupOpen-labelTreatment

Summary

A Phase 3 study to evaluate the safety and efficacy of efgartigimod PH20 subcutaneous in adult patients with primary immune thrombocytopenia

Timeline

Start
2021-11-17
Primary completion
2026-10-01
Completion
2026-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Efgartigimod Alfa Protein / enzyme biologic — Subcutaneous

Indications

autoimmune thrombocytopenia